After completing his training as a physician specializing in infectious diseases and public health in New York City, Dr. Kamran Khan returns to Toronto just before the city’s SARS outbreak begins.
To understand how infectious diseases can spread worldwide, Dr. Khan launches BioDiaspora – a scientific research program to study how the world’s population is connected through commercial air travel.
The research infrastructure developed at St. Michael's Hospital is rapidly applied to anticipate the evolution of the first influenza pandemic of the 21st century, with findings published in the New England Journal of Medicine.
BioDiaspora partners with Public Health England to evaluate local risks from global infectious diseases as the world converges in London for the Olympics. This approach is published in the Lancet Infectious Diseases.
With a vision of using business as a vehicle to address an important social problem, BioDiaspora is incorporated as a Certified B Corporation.
To support growth prospects, BioDiaspora completes a Series A financial investment with Horizons Ventures and renames the company to BlueDot – a metaphor for our small world.